Enhancement Of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma.
Nieto Y, Ramdial J, Valdez B, Thall PF, Bassett R, Barnett M, Srour S, Hosing C, Alousi A, Qazilbash M, Popat U, Gulbis A, Shigle TL, Ahmed S, Guillermo Pacheco M, Champlin R, Shpall EJ, Andersson BS.
Nieto Y, et al. Among authors: ahmed s.
Clin Cancer Res. 2025 Jan 13. doi: 10.1158/1078-0432.CCR-24-3544. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 39804167